SEC Form 6-K filed by Haoxi Health Technology Limited

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December 2025

Commission File Number: 001-41933

Haoxi Health Technology Limited

Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District

Beijing, China

+86-10-13311587976

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒      Form 40-F ☐

Submission of Matters to a Vote of Security Holders.

Haoxi Health Technology Limited (the “Company”) held an extraordinary general meeting of shareholders (the “EGM”) in person at Room 801, Tower C, Floor 8, Building 103, Huizhongli, Chaoyang District, Beijing, China on December 8, 2025 at 10:00AM Eastern Time. Shareholders of the Company’s Class A ordinary shares (the “Class A Ordinary Shares”) and Class B ordinary shares (the “Class B Ordinary Shares”) voted by proxy or at the meeting. Holders of 5,760,234 out of a total of 7,503,028 Class A Ordinary Shares issued and outstanding, and holders of 690,800 out of a total of 690,800 Class B Ordinary Shares issued and outstanding voted at the EGM in person or by proxy. More than one-third (1/3) of the Class A Ordinary Shares and Class B Ordinary Shares, voting together as a single class, entitled to vote at the EGM are represented in person or by proxy, and a quorum for the transaction of business was present at the Meeting. Each Class A Ordinary Share is entitled to one (1) vote and each Class B Ordinary Share is entitled to ten (10) votes. The final voting results for each matter submitted to a vote of shareholders at the meeting are as follows:

Accordingly, the Change of Voting Power has been approved.

Accordingly, the Pre-Consolidation Increase of Authorized Share Capital has been approved.

Accordingly, the Amendment to the Fifth M&A has been approved and adopted.

(a) conditional upon the approval of the Board in its sole discretion, with effect at any time after the conclusion of the Extraordinary Meeting and prior to November 15, 2026 as the Board may determine:

(i) all the issued and unissued Class A ordinary shares and Class B ordinary shares (together, the “Shares”), each of par value $0.0025 per share be consolidated by consolidating at a ratio of no less than two-for-one (2:1) and no more than of one-hundred-and-fifty-for-one (150:1), at any time prior to November 15, 2026, with the exact ratio to be set at a whole number within this range and the exact date to be set as determined by the Board in its sole discretion (the “Share Consolidation”);

(ii) no fractional shares be issued in connection with the Share Consolidation and, in the event that a shareholder would otherwise be entitled to receive a fractional Share upon the Share Consolidation, the total number of Shares to be received by such shareholder be rounded up to the next whole Share; and any change to the Company’s authorized share capital in connection with, and as necessary to effect, the Share Consolidation be and is hereby approved, such amendment to be determined by the Board in its sole discretion; and

(iii) any change to the Company’s authorized share capital in connection with, and as necessary to effect, the Share Consolidation be and is hereby approved, such amendment to be determined by the Board in its sole discretion; and.

(b) the Board be authorized at its absolute and sole discretion to either (i) implement the Share Consolidation and determine the exact consolidation ratio and effective date of such Share Consolidation prior to November 15, 2026 or (ii) elect not to implement the Share Consolidation, and any one director or officer of the Company be and is hereby authorized, for and on behalf of the Company, to do all such other acts or things necessary or desirable to implement, carry out and give effect to the Share Consolidation, if and when deemed advisable by the Board in its sole discretion was as follows:

Accordingly, the Share Consolidation has been approved.

Accordingly, the Post-Consolidation Increase of Authorized Share Capital has been approved.

Accordingly, the Further Amendment to the M&A has been approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.